Bristol-Myers Tops Estimates on Cancer, Hepatitis C SalesBy
Cancer drug Opdivo brings in $305 million, beating estimates
Company raises full-year earnings outlook for third time
Bristol-Myers Squibb Co., a drugmaker increasingly focused on developing new cancer treatments, beat third-quarter profit estimates on better-than-expected revenue from its oncology drug Opdivo and the start of U.S. sales for its hepatitis C drug.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.